Allarity Therapeutics, Inc. (ALLR)

In March 2026, Allarity closed a $20 million non-convertible debt financing with Streeterville Capital. In February 2026, the company announced the dosing of the first patients in a VA-funded Phase 2 trial for small cell lung cancer and opened a new Phase 2 lung cancer study. In November 2025, Allarity Therapeutics reported its Q3 2025 earnings, posting an EPS of -$0.19. In September 2024, the company underwent a 1-for-30 reverse stock split. In March 2025, Allarity Therapeutics initiated a partnership with Shareholder Intelligence Services, LLC to investigate potential illegal naked short selling and other trading irregularities, settled an SEC investigation regarding past FDA disclosures, agreeing to a $2.5 million civil penalty, and the board authorized a stock buyback program of $5,000,000.

As a clinical-stage biopharmaceutical company, Allarity Therapeutics, Inc. does not currently have commercially marketed products with traditional demand seasonality. The company's primary activities are focused on research and development, particularly the clinical development of stenoparib and its DRP® companion diagnostic technology. The demand for these services is driven by the ongoing research and development needs of other biotech companies, which is not typically subject to seasonal fluctuations.

Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing personalized cancer treatments. Its core business revolves around the clinical development of stenoparib and the application of its proprietary Drug Response Predictor (DRP®) companion diagnostic technology. Stenoparib is being evaluated in Phase 2 clinical trials for advanced ovarian cancer and other cancer indications, including small cell lung cancer. The DRP® platform uses gene expression signatures to identify patients most likely to benefit from specific therapies. Allarity also engages in licensing and laboratory services agreements, providing external biotechnology partners with access to DRP® algorithms and transcriptomic testing services.

Allarity Therapeutics is headquartered in Boston, Massachusetts, and maintains a research facility in Denmark. The company operates as a single segment focused on developing ovarian cancer treatments, with activities spanning both Denmark and the United States. Its ongoing clinical trials enroll patients across North America and Europe.

Allarity Therapeutics' reputation has been influenced by both positive clinical advancements and challenges related to market integrity and past regulatory issues. The company has received FDA Fast Track designation for stenoparib in advanced ovarian cancer and reported positive clinical data for stenoparib in ovarian cancer. The expansion of stenoparib development into small cell lung cancer with a VA-funded trial also contributes positively to its scientific and clinical standing. However, the company's reputation has faced scrutiny due to an investigation into potential illegal naked short selling and a settlement with the SEC regarding past FDA disclosures.

Allarity Therapeutics, Inc. has a mix of institutional, individual, and retail ownership. As of March 27, 2026, 16 institutional owners and shareholders have filed 13D/G or 13F forms with the SEC, holding a total of 1,292,104 shares. Institutional investors own approximately 8.17% of the stock, while individual insiders own about 13.31%, and retail investors hold the largest portion at 78.52%. Leon Sass is noted as the largest individual shareholder, owning 1.09 million shares, representing 6.87% of the company.